BeiGene, Ltd. (NASDAQ:BGNE) Short Interest Update

BeiGene, Ltd. (NASDAQ:BGNE) saw a large growth in short interest during the month of August. As of August 31st, there was short interest totalling 2,250,000 shares, a growth of 11.9% from the August 15th total of 2,010,000 shares. Based on an average daily volume of 271,300 shares, the short-interest ratio is presently 8.3 days.

BeiGene Stock Down 1.0 %

Shares of NASDAQ:BGNE traded down $2.04 during midday trading on Monday, hitting $196.45. 200,577 shares of the company’s stock were exchanged, compared to its average volume of 249,254. The company has a market cap of $19.06 billion, a PE ratio of -25.84 and a beta of 0.61. BeiGene has a 12 month low of $126.97 and a 12 month high of $215.00. The stock has a 50 day moving average price of $177.16 and a 200-day moving average price of $163.29. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.98 and a quick ratio of 1.75.

BeiGene (NASDAQ:BGNE) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($1.15) earnings per share for the quarter, topping the consensus estimate of ($2.27) by $1.12. BeiGene had a negative return on equity of 14.93% and a negative net margin of 16.91%. The business had revenue of $929.20 million for the quarter, compared to analysts’ expectations of $810.34 million. During the same quarter in the previous year, the firm earned ($3.64) earnings per share. The business’s revenue was up 56.1% on a year-over-year basis. On average, sell-side analysts anticipate that BeiGene will post -5.13 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on BGNE shares. Bank of America cut their price objective on shares of BeiGene from $180.00 to $152.50 and set a “neutral” rating for the company in a report on Tuesday, July 9th. JPMorgan Chase & Co. boosted their target price on shares of BeiGene from $194.00 to $200.00 and gave the company an “overweight” rating in a research report on Tuesday, August 20th. Finally, Citigroup boosted their target price on shares of BeiGene from $269.00 to $288.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $233.42.

Insider Transactions at BeiGene

In other news, SVP Chan Henry Lee sold 834 shares of the business’s stock in a transaction dated Tuesday, July 30th. The shares were sold at an average price of $160.57, for a total transaction of $133,915.38. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, SVP Chan Henry Lee sold 834 shares of the business’s stock in a transaction dated Tuesday, July 30th. The shares were sold at an average price of $160.57, for a total transaction of $133,915.38. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Titus B. Ball sold 137 shares of BeiGene stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $189.94, for a total transaction of $26,021.78. The disclosure for this sale can be found here. Insiders have sold 13,210 shares of company stock worth $2,269,721 in the last ninety days. Insiders own 7.43% of the company’s stock.

Institutional Investors Weigh In On BeiGene

Hedge funds and other institutional investors have recently modified their holdings of the stock. Jump Financial LLC bought a new stake in shares of BeiGene during the 4th quarter worth $354,000. Dynamic Technology Lab Private Ltd bought a new position in shares of BeiGene in the fourth quarter worth approximately $215,000. BI Asset Management Fondsmaeglerselskab A S purchased a new position in shares of BeiGene in the fourth quarter valued at about $183,000. Trexquant Investment LP bought a new position in BeiGene during the 4th quarter valued at approximately $1,098,000. Finally, BNP Paribas Asset Management Holding S.A. lifted its position in shares of BeiGene by 7.4% in the 4th quarter. BNP Paribas Asset Management Holding S.A. now owns 102,970 shares of the company’s stock worth $18,572,000 after purchasing an additional 7,130 shares during the period. 48.55% of the stock is currently owned by institutional investors.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.